Gina Kolata, a medical reporter for the New York Times, joins Deb Cromer, mother of Kendrick, the first recipient of commercially approved gene therapy for sickle cell anemia. They share Kendrick's journey through this groundbreaking treatment, highlighting the emotional and physical challenges faced by families. The conversation reveals the hopes and fears surrounding this 'cure' and discusses access to innovative healthcare solutions. Deb reflects on her family's resilience, while Kolata emphasizes the importance of empathy in medical care.
Kendrick's gene therapy journey illustrates the potential of innovative treatments to transform lives for sickle cell anemia patients.
The challenges of treatment access reveal systemic healthcare disparities affecting marginalized communities, highlighting urgent needs for equitable solutions.
Deep dives
Understanding Sickle Cell Anemia
Sickle cell anemia is a genetic disorder characterized by the abnormal shape of red blood cells, which can lead to severe complications, including blocking blood flow and causing excruciating pain. The disease affects over 20 million people globally, with a significant concentration among Black communities in the U.S. Kendrick, a 12-year-old boy living with sickle cell anemia, faced numerous health challenges from a young age, including frequent pain crises that often kept him from engaging in normal childhood activities. His family's journey reveals deep emotional and physical struggles associated with managing this lifelong condition, and highlights the urgent need for effective treatments.
The Promise of Gene Therapy
Recent advancements in gene therapy have brought hope to patients suffering from sickle cell anemia, as exemplified by Kendrick, who became the first person to undergo a commercially approved gene therapy procedure. This innovative treatment involves modifying stem cells and reintroducing them into the patient's body, aiming to provide a potential cure for the disease. The therapy not only required rigorous medical procedures but also posed significant risks and challenges, including the need for chemotherapy and extensive hospital stays. Kendrick's story provides a glimpse of hope for many in the sickle cell community, showcasing the potential for these treatments to transform lives.
Access and Implications of Treatment
Despite the promising nature of gene therapy for sickle cell anemia, significant barriers to access remain, with eligibility criteria limiting who can receive treatment. Factors such as age, the frequency of pain crises, and the financial burden associated with therapy present challenges for many patients who may not qualify. It highlights systemic issues within healthcare, including disparities in treatment access and recognition of pain experienced by sickle cell patients, particularly within racially marginalized communities. The Cromer family's experience underscores the need for broader awareness and support systems within the medical community to ensure equitable access to potentially life-saving treatments.
Last May, a 12-year-old with sickle cell anemia was the first person to receive a new gene therapy to treat the disease. The process is painful, expensive, and still frightening and uncertain, but biomedical researchers are cautiously calling it a “cure.”
Guests:
Gina Kolata, medical reporter for the New York Times
Deb and Keith Cromer, parents to Kendric Cromer, the first person in the world to go through a commercially approved gene therapy for sickle cell anemia.
Want more What Next TBD? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen.
Podcast production by Evan Campbell, Patrick Fort, and Cheyna Roth.